Tcelltech Ltd.

Phase Ia: Dose escalation phase Main objectives: 1) Evaluate the safety and tolerability of intravenous or intraperitoneal infusion of TX103 CAR-T cells; 2) Determine the maximum tolerated dose (MTD) and/or recommended dose for phase 2 (RP2D) of intravenous or intraperitoneal infusion of TX103 CAR-T cells based on dose-limiting toxicity (DLT) and/or optimal biological dose Secondary objectives: 1) Evaluate the efficacy of intravenous or intraperitoneal infusion of TX103 CAR-T cells; 2) Evaluate the clinical pharmacological characteristics of different administration routes and dosages of TX103 CAR-T. Phase Ib: Extension phase Main objectives: Explore the population of subjects that may benefit and preliminarily evaluate the anti-tumor activity of intravenous or intraperitoneal infusion of TX103 CAR-T cells. Secondary objectives: 1) To evaluate the safety of intravenous or intraperitoneal reinfusion of TX103 CAR-T cells; 2) To evaluate the clinical pharmacological characteristics of TX103CAR-T at different administration routes and dosages.